Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
Transparent and comprehensive information is the foundation of our corporate communications. Current press releases and an archive of press releases to the year 2008 can be found here.
PAION announces approval of compassionate use for remimazolam in Italian hospital
PAION closes enrollment in EU Phase III trial with remimazolam in general anesthesia
PAION AG reports on fiscal year 2019
PAION AG: Cosmo announces brief extension of FDA review period for NDA for remimazolam
Cosmo sub-licenses its ByFavo™ (Remimazolam) US rights to Acacia Pharma, takes an initial 14.1% stake and provides finance for Acacia Pharma’s US expansion
PAION grants remimazolam license for Southeast Asia to Hana Pharm